Stress relief for cancer immunotherapy: implications for the ER stress response in tumor immunity Alex M. AndrewsMegan D. TennantJessica E. Thaxton Review 26 October 2020 Pages: 1165 - 1175
Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy Elena María Brozos-VázquezRoberto Díaz-PeñaRafael López-López Review 28 October 2020 Pages: 1177 - 1188
Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer Tao DaoMartin G. KlattDavid A. Scheinberg Original Article 29 October 2020 Pages: 1189 - 1202
Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect Jiyun LeeBinnari KimJong-Mu Sun Original Article 29 October 2020 Pages: 1203 - 1211
B7-H3 confers resistance to Vγ9Vδ2 T cell-mediated cytotoxicity in human colon cancer cells via the STAT3/ULBP2 axis Huimin LuYanchao MaWeichang Chen Original Article 29 October 2020 Pages: 1213 - 1226
Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas Farah SuccariaPia KvistborgJanis M. Taube Original Article 30 October 2020 Pages: 1227 - 1237
CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy Ayaka HaraRyo Koyama-NasuShinichiro Motohashi Original Article Open access 31 October 2020 Pages: 1239 - 1254
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2 Michael MarkPatrizia Froeschfor the Swiss Group for Clinical Cancer Research (SAKK) Original Article 01 November 2020 Pages: 1255 - 1262
Noninvasive, longitudinal imaging-based analysis of body adipose tissue and water composition in a melanoma mouse model and in immune checkpoint inhibitor-treated metastatic melanoma patients Wolfgang M. ThaissSergios GatidisManfred Kneilling Original Article Open access 01 November 2020 Pages: 1263 - 1275
Granzyme B in peripheral blood mononuclear cells as a measure of cell-mediated immune response in paraneoplastic neurological syndromes and malignancy Mikołaj Piotr ZaborowskiPatrycja Stefens-StawnaSławomir Michalak Original Article Open access 02 November 2020 Pages: 1277 - 1289
Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters Lata SinghMithalesh Kumar SinghSeema Kashyap Original Article 02 November 2020 Pages: 1291 - 1303
IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells J. M. R. Van der MeerR. J. A. MaasH. Dolstra Original Article Open access 03 November 2020 Pages: 1305 - 1321
In vitro and in vivo evaluation of anti-tumoral effect of M1 phenotype induction in macrophages by miR-130 and miR-33 containing exosomes Maryam Moradi-ChaleshtoriMojgan BandehpourSeyed Mahmoud Hashemi Original Article 03 November 2020 Pages: 1323 - 1339
Correction to: In vitro and in vivo evaluation of anti‑tumoral effect of M1 phenotype induction in macrophages by miR‑130 and miR‑33 containing exosomes Maryam Moradi-ChaleshtoriMojgan BandehpourSeyed Mahmoud Hashemi Correction 05 December 2020 Pages: 1341 - 1341
The role of dendritic cells for therapy of B-cell lymphoma with immune checkpoint inhibitors Anne ScheuerpflugFatima AhmetlićRalph Mocikat Original Article Open access 03 November 2020 Pages: 1343 - 1350
Nicotine exhausts CD8+ T cells against tumor cells through increasing miR-629-5p to repress IL2RB-mediated granzyme B expression Chun-Chia ChengHsin-Chi LinYi-Fang Chang Original Article 03 November 2020 Pages: 1351 - 1364
Prognostic significance of S100A8-positive immune cells in relation to other immune cell infiltration in pre-invasive and invasive breast cancers Ji Won WooYul Ri ChungSo Yeon Park Original Article Open access 04 November 2020 Pages: 1365 - 1378
IL-10, IL-13, Eotaxin and IL-10/IL-6 ratio distinguish breast implant-associated anaplastic large-cell lymphoma from all types of benign late seromas Arianna Di NapoliDaniele GrecoMarshall E. Kadin Original Article Open access 04 November 2020 Pages: 1379 - 1392
Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study of a single institution R. KleefR. NagyT. Bakacs Original Article Open access 05 November 2020 Pages: 1393 - 1403
Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma Yusuke MochizukiHiroshi TazawaToshiyoshi Fujiwara Original Article 05 November 2020 Pages: 1405 - 1417
Combination of novel intravesical xenogeneic urothelial cell immunotherapy and chemotherapy enhances anti-tumor efficacy in preclinical murine bladder tumor models Chi-Ping HuangChun-Chie WuChih-Rong Shyr Original Article Open access 06 November 2020 Pages: 1419 - 1433
The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer Ming-Fang WuChih-An LinHuei-Wen Chen Original Article Open access 11 November 2020 Pages: 1435 - 1450
Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells Farsaneh SadeghlarAnnabelle VogtMaria A. González-Carmona Original Article Open access 12 November 2020 Pages: 1451 - 1464
Correlation of tumor microenvironment from biopsy and resection specimens in untreated colorectal cancer patients: a surprising lack of agreement Phillip M. Kemp BohanRobert C. ChickGuy T. Clifton Original Article 12 November 2020 Pages: 1465 - 1474
Modeling of tumor response to macrophage and T lymphocyte interactions in the liver metastatic microenvironment Louis T. CurtisSusanne SebensHermann B. Frieboes Original Article 12 November 2020 Pages: 1475 - 1488
Correction to: Modeling of tumor response to macrophage and T lymphocyte interactions in the liver metastatic microenvironment Louis T. CurtisSusanne SebensHermann B. Frieboes Correction 05 January 2021 Pages: 1489 - 1489
Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma M. SchuivelingE. H. J. TonkK. P. M. Suijkerbuijk Research Report Open access 14 September 2020 Pages: 1491 - 1496